{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:46:57Z","timestamp":1792111617978,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jgo.2026.104640","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:39:11Z","timestamp":1792100351000},"page":"104640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Frailty score, sarcopenia, and myosteatosis: Stratifying risk and outcomes in non-transplant eligible patients with multiple myeloma treated with daratumumab-based dose-adjusted combination therapies"],"prefix":"10.1016","volume":"18","author":[{"given":"Sofia","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Frittoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Ribolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bianchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Vietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Avenoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jgo.2026.104640_bb0005","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2026.104640_bb0010","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European myeloma network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jgo.2026.104640_bb0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cncr.34545","article-title":"Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma","volume":"129","author":"Nandakumar","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jgo.2026.104640_bb0020","doi-asserted-by":"crossref","first-page":"7937","DOI":"10.21037\/qims-24-365","article-title":"Myosteatosis: diagnostic significance and assessment by imaging approaches","volume":"14","author":"Garcia-Diez","year":"2024","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"10.1016\/j.jgo.2026.104640_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00256-024-04735-y","article-title":"Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia","volume":"54","author":"Diallo","year":"2025","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jgo.2026.104640_bb0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.jgo.2026.104640_bb0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2026.104640_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-025-06190-1","article-title":"Different cutoff values of the skeletal muscle mass and myosteatosis result in different clinical impact on overall survival in oncology. A subanalysis of a clinical trial","volume":"151","author":"Surov","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2026.104640_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102051","article-title":"Evaluating concordance between international myeloma working group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma","volume":"15","author":"Gahagan","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.104640_bb0050","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2026.104640_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"EHA guidelines committee. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.jgo.2026.104640_bb0060","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2026.104640_bb0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jgo.2026.104640_bb0070","article-title":"Fat infiltration in skeletal muscle: influential triggers and regulatory mechanism","author":"Wang","year":"2024","journal-title":"iScience"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826017972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826017972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:17:11Z","timestamp":1792109831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826017972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1879406826017972"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104640","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty score, sarcopenia, and myosteatosis: Stratifying risk and outcomes in non-transplant eligible patients with multiple myeloma treated with daratumumab-based dose-adjusted combination therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104640"}}